Market closedNon-fractional
ImmunoPrecise Antibodies/IPA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About ImmunoPrecise Antibodies
ImmunoPrecise Antibodies Ltd is a supplier of custom antibodies to the research industry and industrial community. The company has aggregated its operations into one reportable segment, Antibody Production, and Related Services. It operates in three principal geographical areas - the United States of America, Canada, Europe, and others. The majority of its revenue is derived from Europe.
Ticker
IPA
Sector
Healthcare
Trading on
NASDAQ
Industry
Life Sciences Tools and Services
Headquarters
Victoria, Canada
Employees
102
Website
www.ipatherapeutics.com
IPA Metrics
BasicAdvanced
$22M
Market cap
-
P/E ratio
-$0.41
EPS
0.36
Beta
-
Dividend rate
Price and volume
Market cap
$22M
Beta
0.36
Financial strength
Current ratio
1.657
Quick ratio
1.176
Long term debt to equity
25.338
Total debt to equity
28.887
Management effectiveness
Return on assets (TTM)
-10.99%
Return on equity (TTM)
-25.72%
Valuation
Price to revenue (TTM)
1.228
Price to book
0.45
Price to tangible book (TTM)
6.71
Price to free cash flow (TTM)
-6.362
Growth
Revenue change (TTM)
16.75%
Earnings per share change (TTM)
-48.35%
3-year revenue growth (CAGR)
11.29%
3-year earnings per share growth (CAGR)
38.20%
What the Analysts think about IPA
Analyst Ratings
Majority rating from 2 analysts.
IPA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
-$0.21
-$0.14
-$0.10
-$0.11
-
Expected
-$0.17
-$0.21
-$0.13
-$0.10
-$0.12
Surprise
23.53%
-31.71%
-23.08%
10.00%
-
IPA News
AllArticlesVideos
ImmunoPrecise Antibodies to Reschedule Financial Results and Recent Business Highlights Report for Fourth Quarter and Fiscal Year-End 2024
Business Wire·3 days ago
IPA's Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai™
Business Wire·1 month ago
BioStrand, ImmunoPrecise Antibodies' Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ImmunoPrecise Antibodies stock?
ImmunoPrecise Antibodies (IPA) has a market cap of $22M as of July 27, 2024.
What is the P/E ratio for ImmunoPrecise Antibodies stock?
The price to earnings (P/E) ratio for ImmunoPrecise Antibodies (IPA) stock is 0 as of July 27, 2024.
Does ImmunoPrecise Antibodies stock pay dividends?
No, ImmunoPrecise Antibodies (IPA) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next ImmunoPrecise Antibodies dividend payment date?
ImmunoPrecise Antibodies (IPA) stock does not pay dividends to its shareholders.
What is the beta indicator for ImmunoPrecise Antibodies?
ImmunoPrecise Antibodies (IPA) has a beta rating of 0.36. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell ImmunoPrecise Antibodies stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.